Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

Status Suspended

Clinical Trial Summary

Clinical Trial Description

The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana [Delta-9-tetrahydracannabinol (THC)] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability. Marijuana plant material will be obtained from the National Institutes on Drug Abuse (NIDA). In clinical studies, oral synthetic THC reduced the severity of opioid withdrawal during opioid detoxification. Clinically, cannabinoid drugs like Marinol® (oral synthetic THC), Sativex ® (nabixomols), and Cesamet® (nabilone) are used to treat nausea and vomiting, common symptoms of opioid withdrawal. This study will investigate the ability of vaporized marijuana (V-MJ) (0.00, 12.5, and 25 mg: concentration= 11.7% THC + 0.04% CBD) to reduce the severity of opioid withdrawal precipitated by intranasal (IN) NLX (0.0 and 4.0 mg). This trial will recruit healthy participants with opioid use disorder (N=16, completers). Testing will begin following stabilization on oral morphine (120 mg/day), which will continue throughout the trial. During each testing session, a single V-MJ + naloxone dose combination will be assessed (in randomized order), with 48 hours between testing sessions. Laboratory testing sessions will consist of a modified naloxone challenge procedure, which quantifies the severity of naloxone-precipitated opioid withdrawal. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05114460
Study type	Interventional
Source	New York State Psychiatric Institute
Contact
Status	Suspended
Phase	Phase 2
Start date	November 1, 2021
Completion date	December 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04372238` - The Rhode Island Prescription and Illicit Drug Study	N/A
Recruiting	`NCT03924505` - Preventing Opioid Overdose Mortality in the United States	N/A
Completed	`NCT05093309` - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone	N/A
Completed	`NCT05219669` - Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens	Phase 1
Completed	`NCT04317053` - Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program	Phase 3
Not yet recruiting	`NCT06466005` - UnityPhilly Response App for Overdose Reversal
Recruiting	`NCT04815590` - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Active, not recruiting	`NCT05096429` - Preventing Overdose Using Information and Data From the Environment	N/A
Recruiting	`NCT06238128` - Opioid Rapid Response System: Naloxone Training in Communities	N/A
Completed	`NCT02662153` - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Active, not recruiting	`NCT05944133` - Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
Completed	`NCT05377255` - Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults	Phase 1
Recruiting	`NCT05877118` - Improving Availability of Intranasal Naloxone	N/A
Recruiting	`NCT05072249` - European Cohort Study of the Effectiveness of Take Home Naloxone
Withdrawn	`NCT05808881` - Clinical Outcomes From Nalmefene	Phase 4
Not yet recruiting	`NCT01622504` - Naloxone Nasal Spray Pharmacokinetic Study	Phase 1
Not yet recruiting	`NCT06429436` - Vending Machine Naloxone Distribution for Your Community (VENDY)	Phase 4
Completed	`NCT05506267` - Development of a Tracheal Sound Sensor
Completed	`NCT02535494` - Risks and Benefits of Naloxone Prescribing	N/A
Not yet recruiting	`NCT06408714` - Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose	Phase 3